Clinical Study
Real-Life Report on Chemoembolization Using DEBIRI for Liver Metastases from Colorectal Cancer
Table 1
Patient characteristics.
| | Patient characteristics |
| | Median age, years (range) | 57, (45–82) |
| | | Patient number; | Percent |
| | Gender (M/F) | 16/11 | 60/40 | | Prior hepatic procedure | | | | PVE | 1 | 3.5 | | H. lobectomy | 4 | 15 | | PVE + h. lobectomy | 2 | 7.5 | | PVE + RFA | 1 | 3.5 | | RFA + h. lobectomy | 4 | 15 | | PVE + RFA + h. lobectomy | 3 | 11 | | Total | 15 | 55.5 | |
ECOG performance status | | | | 0 | 14 | 56 | | 1 | 9 | 36 | | 2 | 2 | 8 | | Extrahepatic disease (Y/N) | 11/16 | 40/60 |
| | Previous medical history | Number of patients; | Percent |
| | Diabetes | 4 | 15 | | Cardiac | 4 | 15 | | Hypertension | 12 | 45 | | Previous cancer | 3 | 11 | | Breast | 2 | 7.5 | | Prostate | 1 | 3.5 |
| | Previous chemotherapy |
| | Number of previous lines failed | Number of patients; = 27 | Percent |
| | 1 | 8 | 30 | | 2 | 12 | 44 | | 3 | 4 | 15 | | 4 | 2 | 7 | | 5 | 1 | 4 | | Average chemotherapy lines/patient | 2 | | | First line | | | | FOLFOX ± bevacizumab (+/−) | 21 (17/4) | 78 | | FOLFIRI ± bevacizumab (+/−) | 5 (3/2) | 18.5 | | FOLFIRINOX ± bevacizumab | 1 | 3.5 | | Second line | | | | FOLFOX ± bevacizumab (+/−) | 5 (4/1) | 26 | | FOLFIRI ± bevacizumab | 12 (9/3) | 64 | | FOLFIRI + pentamidine | 1 | 5 | | XELIRI + cetuximab | 1 | 5 | | Postembolization treatment | | | | Chemotherapy | 7 | 26 | | Panitumumab | 4 | 15 | | Total | 11 | 41 |
|
|
